Dimerix Bioscience
Latest round
- Series A
Last raised
- Sep 2005
Total raised
- $0.8M
Investors
- 2
About Dimerix Bioscience
Founded in 2004 and headquartered in Melbourne, Australia, Dimerix Bioscience specializes in developing biopharmaceutical products. The company was involved in three deals, with the most recent occurring on July 3, 2015, when it was acquired by Sun Biomedical Limited.Dimerix Limited specializes in developing biopharmaceutical products aimed at addressing significant unmet needs in inflammatory diseases, particularly kidney and respiratory conditions. The company’s lead product, DMX-200, is currently undergoing Phase 3 clinical trials for its application in treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. This investigational medication leverages Dimerix’s proprietary Receptor-HIT technology, which identifies and develops drugs that target specific receptor interactions to improve therapeutic outcomes. Dimerix aims to commercialize its products in global markets, focusing on regions with high demand for effective treatments for complex inflammatory diseases.Dimerix Limited operates through a structured transaction model primarily involving collaborative partnerships and agreements with pharmaceutical companies and research institutions.90. Revenue generation is anticipated to stem from successful clinical development milestones related to DMX-200, as well as potential licensing agreements or joint ventures that facilitate market entry for its therapies.Dimerix is focused on launching its lead product DMX-200, expected to progress through clinical development milestones that will enhance its market readiness. The company is targeting expansion into global markets with high demand for therapies addressing inflammatory diseases.40 mn will support these initiatives, including furthering the development of DMX-200 and pursuing strategic partnerships to aid in the commercialization of its products.
Who invested in Dimerix Bioscience
2 investors across 1 round
See all investors in Dimerix Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 15, 2005
Amount
$0.8M
Investors
Questions about Dimerix Bioscience
Who invested in Dimerix Bioscience?
Dimerix Bioscience has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Dimerix Bioscience raised?
Dimerix Bioscience has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Dimerix Bioscience last raise money?
Dimerix Bioscience's most recent round on record is a Series A, in Sep 2005.
What does Dimerix Bioscience do?
Founded in 2004 and headquartered in Melbourne, Australia, Dimerix Bioscience specializes in developing biopharmaceutical products.
Where is Dimerix Bioscience headquartered?
Dimerix Bioscience is headquartered in Melbourne, Australia.
Which VCs invest in companies like Dimerix Bioscience?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back pharmaceuticals companies at Dimerix Bioscience's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Dimerix Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.